Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : ADVR:THE NEW COMPANY...WITH A NEW LIFE...AND A NEW MISSION -- Ignore unavailable to you. Want to Upgrade?

To: OLD JAKE JUSTUS who wrote (376)	6/11/1998 4:08:00 PM
From: DAN LITTLE	Read Replies (2) \| Respond to of 4891

This is the first time I have seen any public release on the Mexico trials. By my calculations they must be in phase two trials by now. The only problem with that theory is that ADVR has to be stretched very very thin with the amount of available Reticulose and amount that can be made weekly. If you figure the numbers they cannot manufacture enough to start any new trials here or anywhere else. They will need to complete the present trials before starting anything new. They could get the IND and start the preliminary steps for phase 1 FDA and by then the Argentina trials should be over. I think that the FDA already has the results of the NCI research, the Safety study, The Hirschman report and the Barbados trials. I think the IND is in the bag and if ADVR had a larger bankroll we would be in phase two FDA trials right now. We are playing the game of hurry up and wait. Around last Oct. Joe said that it would take about a year for ADVR to start moving. I believe that his prediction is the closest to the target then anything that anyone has ever said on this thread. We have never been very well informed so maybe they are already manufacturing Reticulose in Argentina or maybe they are closer to a new manufacturing plant then we think. Anyway production needs to be increased big time and soon. JMHO, Dan